292,746 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Acquired by Norges Bank

Norges Bank purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 292,746 shares of the medical equipment provider’s stock, valued at approximately $26,189,000. Norges Bank owned approximately 0.42% of Lantheus as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus in the third quarter worth approximately $25,000. Kestra Investment Management LLC purchased a new position in Lantheus during the 4th quarter worth approximately $27,000. UMB Bank n.a. raised its stake in Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares during the period. World Investment Advisors LLC purchased a new stake in shares of Lantheus in the third quarter valued at $60,000. Finally, Parkside Financial Bank & Trust boosted its position in shares of Lantheus by 49.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock worth $76,000 after buying an additional 280 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. JMP Securities reissued a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial boosted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. B. Riley decreased their target price on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Finally, The Goldman Sachs Group began coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $129.43.

Insider Activity at Lantheus

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 64,109 shares of company stock worth $6,110,806 in the last 90 days. 2.00% of the stock is owned by company insiders.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $90.92 on Monday. The business’s 50-day simple moving average is $93.31 and its 200-day simple moving average is $96.03. Lantheus Holdings, Inc. has a 52 week low of $58.46 and a 52 week high of $126.89. The firm has a market cap of $6.23 billion, a price-to-earnings ratio of 15.13 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.